NO20005913L - Legemiddelsammensetning - Google Patents
LegemiddelsammensetningInfo
- Publication number
- NO20005913L NO20005913L NO20005913A NO20005913A NO20005913L NO 20005913 L NO20005913 L NO 20005913L NO 20005913 A NO20005913 A NO 20005913A NO 20005913 A NO20005913 A NO 20005913A NO 20005913 L NO20005913 L NO 20005913L
- Authority
- NO
- Norway
- Prior art keywords
- medicinal composition
- medicinal
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14091598 | 1998-05-22 | ||
| PCT/JP1999/002681 WO1999061061A1 (fr) | 1998-05-22 | 1999-05-21 | Composites medicamenteux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20005913D0 NO20005913D0 (no) | 2000-11-22 |
| NO20005913L true NO20005913L (no) | 2001-01-22 |
Family
ID=15279786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005913A NO20005913L (no) | 1998-05-22 | 2000-11-22 | Legemiddelsammensetning |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6835807B1 (fr) |
| EP (1) | EP1080732A4 (fr) |
| JP (1) | JP4560210B2 (fr) |
| KR (1) | KR100581443B1 (fr) |
| CN (1) | CN1250293C (fr) |
| AU (1) | AU3733399A (fr) |
| CA (1) | CA2333321A1 (fr) |
| EA (1) | EA003398B1 (fr) |
| HK (1) | HK1040052B (fr) |
| NO (1) | NO20005913L (fr) |
| TW (1) | TWI253935B (fr) |
| WO (1) | WO1999061061A1 (fr) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| BR9915198A (pt) | 1998-10-30 | 2001-08-14 | Daiichi Seiyaku Co | Composto dds e método para medição do mesmo |
| WO2002000734A1 (fr) * | 2000-06-29 | 2002-01-03 | Daiichi Pharmaceutical Co., Ltd. | Compose dds et son procede de preparation |
| TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
| WO2004054622A1 (fr) * | 2002-12-13 | 2004-07-01 | Immunomedics, Inc. | Immunoconjugues comprenant une liaison intracellulaire clivable |
| US7282590B2 (en) * | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
| US7375078B2 (en) * | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| EP1973952A4 (fr) * | 2006-01-23 | 2010-09-01 | Kwangju Inst Sci & Tech | Conjugué comprenant un composé pharmaceutiquement actif lié de façon covalente à un polymère mucoadhésif et méthode d'administration transmucosale de composé pharmaceutiquement actif faisant appel audit conjugué |
| CN1973902B (zh) * | 2006-12-12 | 2010-11-10 | 东北师范大学 | 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法 |
| EP2279006B1 (fr) * | 2008-04-22 | 2014-10-22 | FIDIA FARMACEUTICI S.p.A. | Utilisation thérapeutique de préparations pharmaceutiques contenant des antitumoraux liés à l'acide hyaluronique dans le traitement des néoplasies |
| WO2011130598A1 (fr) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazépines et conjugués de celles-ci |
| DK2576638T3 (da) | 2010-05-25 | 2021-03-15 | Syndevrx Inc | Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| US11135303B2 (en) | 2011-10-14 | 2021-10-05 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| RS62689B1 (sr) | 2011-11-04 | 2021-12-31 | Zymeworks Inc | Dizajn stabilnog heterodimernog antitela sa mutacijama u fc domenu |
| WO2013177481A1 (fr) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazépines et leurs conjugués |
| DK2907824T3 (en) | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| WO2014057114A1 (fr) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Conjugués pyrrolobenzodiazepine-anticorps anti-psma |
| CA2887895C (fr) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Conjugues d'anticorps cd19-anti-pyrrolobenzodiazepine |
| CN105102003B (zh) | 2012-10-12 | 2019-03-05 | Adc疗法责任有限公司 | 吡咯并苯并二氮杂卓-抗psma抗体结合物 |
| JP6392765B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ | ピロロベンゾジアゼピン−抗体結合体 |
| EP2839860B1 (fr) | 2012-10-12 | 2019-05-01 | MedImmune Limited | Pyrrolobenzodiazépines et ses conjugués |
| EP2906297B1 (fr) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Conjugués anticorps - pyrrolobenzodiazépine |
| MX364328B (es) | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Conjugados del anticuerpo pirrolobenzodiazepina. |
| ES2782248T3 (es) * | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila |
| WO2014096365A1 (fr) | 2012-12-21 | 2014-06-26 | Spirogen Sàrl | Dimères de pyrrolobenzodiazépines asymétriques à utiliser dans le traitement de maladies prolifératives et auto-immunes |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| BR112015021965B1 (pt) | 2013-03-13 | 2022-05-03 | Medimmune Limited | Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos |
| KR102057755B1 (ko) | 2013-03-13 | 2019-12-19 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
| JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びその結合体 |
| JP6420314B2 (ja) | 2013-04-10 | 2018-11-07 | シンデブルックス，インコーポレイティド | Ｍｅｔａｐ２阻害剤及び肥満症の治療方法 |
| EP3054985B1 (fr) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Conjugués anticorps-pyrrolobenzodiazépine |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054983B1 (fr) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Conjugués anticorps-pyrrolobenzodiazépines |
| US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
| SI3088419T1 (sl) | 2013-12-25 | 2019-01-31 | Daiichi Sankyo Company | Zdravilni konjugat anti trop2 protitelesa |
| DK3466976T3 (da) | 2014-01-31 | 2021-12-13 | Daiichi Sankyo Co Ltd | Anti-her2-antistof-lægemiddelkonjugat |
| US10550190B2 (en) | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
| ES2754348T3 (es) * | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugado de (anticuerpo anti-HER2)-fármaco |
| KR102351755B1 (ko) | 2014-04-10 | 2022-01-14 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CA2968447A1 (fr) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Conjugues anticorps-pyrrolobenzodiazepine |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| AU2016286898B2 (en) | 2015-06-29 | 2022-12-08 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| WO2017062334A1 (fr) | 2015-10-05 | 2017-04-13 | Merck Sharp & Dohme Corp. | Conjugués anticorps-peptides ayant une activité agoniste au niveau des récepteurs au glucagon et au peptide-1 similaire au glucagon |
| EP3359194A4 (fr) | 2015-10-06 | 2019-04-24 | Merck Sharp & Dohme Corp. | Conjugué anticorps-médicament pour applications anti-inflammatoires |
| CA3005450A1 (fr) | 2015-12-10 | 2017-06-15 | Syndevrx, Inc. | Derives de fumagillol et leurs polymorphes |
| JP7022066B2 (ja) | 2016-01-11 | 2022-02-17 | シンデブルックス，インコーポレイティド | 代謝機能不全によって引き起こされる腫瘍の治療 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| US10869929B2 (en) | 2016-01-29 | 2020-12-22 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| WO2018110515A1 (fr) | 2016-12-12 | 2018-06-21 | 第一三共株式会社 | Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle immunitaire |
| KR102537651B1 (ko) | 2017-01-17 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트 |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| JP6671555B2 (ja) | 2017-02-08 | 2020-03-25 | アーデーセー セラピューティクス ソシエテ アノニム | ピロロベンゾジアゼピン抗体複合体 |
| JP2020517609A (ja) | 2017-04-18 | 2020-06-18 | メディミューン リミテッド | ピロロベンゾジアゼピン複合体 |
| CA3057748A1 (fr) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Polytherapie avec un conjugue anticorps anti-axl-medicament |
| TWI794230B (zh) | 2017-05-15 | 2023-03-01 | 日商第一三共股份有限公司 | 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法 |
| WO2018229222A1 (fr) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Régimes posologiques pour l'administration d'un cam anti-cd19 |
| WO2019034764A1 (fr) | 2017-08-18 | 2019-02-21 | Medimmune Limited | Conjugués de pyrrolobenzodiazépine |
| CA3073924C (fr) | 2017-08-31 | 2023-10-17 | Daiichi Sankyo Company, Limited | Procede ameliore de production d'un conjugue anticorps-medicament |
| BR112020003466B1 (pt) | 2017-08-31 | 2023-12-12 | Daiichi Sankyo Company, Limited | Métodos de produção de composto, e, composto |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| JP2021524740A (ja) | 2018-05-18 | 2021-09-16 | グリコトープ ゲーエムベーハー | 抗ｍｕｃ１抗体 |
| CN112739340A (zh) | 2018-07-23 | 2021-04-30 | 美真达治疗公司 | 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| EP3870231A1 (fr) | 2018-10-26 | 2021-09-01 | Syndevrx, Inc. | Biomarqueurs d'inhibiteurs de metap2 et leurs applications |
| US20230135930A1 (en) | 2019-04-24 | 2023-05-04 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| CN110339181A (zh) * | 2019-07-02 | 2019-10-18 | 中国药科大学 | 一种基于点击反应的pH响应型纳米制剂及其制法和应用 |
| PE20220563A1 (es) | 2019-07-10 | 2022-04-13 | Cybrexa 2 Inc | Conjugados peptidicos de citotoxinas como terapeuticos |
| CN114302744A (zh) | 2019-07-10 | 2022-04-08 | 赛博克萨3公司 | 作为治疗剂的微管靶向剂的肽缀合物 |
| EP4096717A1 (fr) * | 2020-01-31 | 2022-12-07 | Innate Pharma | Traitement du cancer |
| WO2022043256A1 (fr) | 2020-08-23 | 2022-03-03 | Cobiores Nv | Combinaisons synergiques de médicaments anticancéreux liés à une fraction tétrapeptidique et d'agents immunothérapeutiques |
| EP4251207A1 (fr) | 2020-11-25 | 2023-10-04 | Innate Pharma | Traitement du cancer |
| CA3203072A1 (fr) | 2020-12-22 | 2022-06-30 | Andrea CASAZZA | Composes comprenant une fraction tetrapeptidique |
| WO2022167664A1 (fr) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Composés comprenant une fraction tétrapeptidique |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| US20230355792A1 (en) | 2022-04-07 | 2023-11-09 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index |
| WO2023227660A1 (fr) | 2022-05-25 | 2023-11-30 | Innate Pharma | Agents de liaison à la nectine-4 |
| WO2024121632A1 (fr) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Utilisation d'un conjugué anticorps-médicament (adc) anti-cd117 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69225542T2 (de) | 1991-02-21 | 1998-09-10 | Drug Delivery System Inst Ltd | Carboxymethylmannoglukan und derivate davon |
| JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| CA2134348C (fr) * | 1993-02-26 | 2007-01-02 | Hideo Nogusa | Derives polysaccharidiques et vecteurs de medicaments |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| JPH0784481A (ja) | 1993-06-26 | 1995-03-31 | Ricoh Co Ltd | 画像形成装置 |
| CA2192725C (fr) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Derives de la camptothecine |
| TW409058B (en) * | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| US6368598B1 (en) * | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
| AU739028B2 (en) | 1996-09-27 | 2001-10-04 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
| AU5159798A (en) * | 1996-11-05 | 1998-05-29 | Bristol-Myers Squibb Company | Branched peptide linkers |
| JPH1171280A (ja) * | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JPH1192405A (ja) * | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | 薬物複合体 |
| BR9915198A (pt) * | 1998-10-30 | 2001-08-14 | Daiichi Seiyaku Co | Composto dds e método para medição do mesmo |
-
1999
- 1999-05-21 CN CNB998089796A patent/CN1250293C/zh not_active Expired - Fee Related
- 1999-05-21 EA EA200001217A patent/EA003398B1/ru not_active IP Right Cessation
- 1999-05-21 WO PCT/JP1999/002681 patent/WO1999061061A1/fr active IP Right Grant
- 1999-05-21 TW TW088108351A patent/TWI253935B/zh not_active IP Right Cessation
- 1999-05-21 EP EP99919664A patent/EP1080732A4/fr not_active Withdrawn
- 1999-05-21 AU AU37333/99A patent/AU3733399A/en not_active Abandoned
- 1999-05-21 CA CA002333321A patent/CA2333321A1/fr not_active Abandoned
- 1999-05-21 US US09/674,526 patent/US6835807B1/en not_active Expired - Fee Related
- 1999-05-21 KR KR1020007013102A patent/KR100581443B1/ko not_active IP Right Cessation
- 1999-05-21 JP JP2000550520A patent/JP4560210B2/ja not_active Expired - Fee Related
-
2000
- 2000-11-22 NO NO20005913A patent/NO20005913L/no not_active Application Discontinuation
-
2002
- 2002-02-22 HK HK02101369.9A patent/HK1040052B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3733399A (en) | 1999-12-13 |
| HK1040052B (zh) | 2006-09-15 |
| KR20010052385A (ko) | 2001-06-25 |
| US6835807B1 (en) | 2004-12-28 |
| NO20005913D0 (no) | 2000-11-22 |
| EA200001217A1 (ru) | 2001-06-25 |
| EP1080732A1 (fr) | 2001-03-07 |
| EP1080732A4 (fr) | 2004-08-25 |
| EA003398B1 (ru) | 2003-04-24 |
| JP4560210B2 (ja) | 2010-10-13 |
| KR100581443B1 (ko) | 2006-05-23 |
| CA2333321A1 (fr) | 1999-12-02 |
| HK1040052A1 (en) | 2002-05-24 |
| WO1999061061A1 (fr) | 1999-12-02 |
| TWI253935B (en) | 2006-05-01 |
| CN1250293C (zh) | 2006-04-12 |
| CN1310631A (zh) | 2001-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20005913L (no) | Legemiddelsammensetning | |
| ID27415A (id) | Komposisi farmaseutik | |
| EA199900373A3 (ru) | Фармацевтические композиции | |
| ID26186A (id) | Komposisi sampo | |
| ID28694A (id) | Komposisi sampo | |
| ID26720A (id) | Komposisi oral | |
| ID29430A (id) | Komposisi herbisida | |
| ID20233A (id) | Komposisi oral | |
| NO20004758L (no) | Vaksinesammensetning | |
| ID29262A (id) | Komposisi farmasi | |
| NO992692L (no) | Nefadozon doseringsform | |
| DK1466615T3 (da) | Farmaceutisk præparat | |
| DE69942892D1 (de) | Gaserzeugende zusammensetzung | |
| DE69928862D1 (de) | Zusammensetzung | |
| ID27201A (id) | Komposisi farmasi | |
| DK1023035T3 (da) | Mundplejemiddel | |
| ID20466A (id) | Komposisi oral | |
| ID29294A (id) | Komposisi farmasi | |
| ID25857A (id) | Komposisi farmasi | |
| ID26295A (id) | Komposisi keras-ultraviolet | |
| ID26215A (id) | Komposisi farmasi | |
| ID26485A (id) | Komposisi paroksetina | |
| FI19992526A (fi) | Sahakokoonpano | |
| ID28359A (id) | Komposisi | |
| DE69939964D1 (de) | Gelförmige Zusammensetzung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |